Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Ebola has left those living in the country’s east weary and fearful, and, just as they were preparing to declare an end to the outbreak, a new case popped up. Now, they will now have to manage both threats at once. The new virus has overwhelmed some of the world’s best hospital systems in Europe and ripped through communities in New York. In Congo, it could spread unchecked in a country that has endured decades of conflict, where corruption has left the the population largely impoverished despite mineral wealth, and where mistrust of authority is so entrenched that health workers have been killed during the Ebola outbreak. It’s also unclear how forthcoming international support will be at a time when the whole world is battling the coronavirus. “It all feels like one big storm,” said Martine Milonde, a Congolese community mobilizer who works with the aid group World Vision in Beni, which has been the epicenter of the Ebola outbreak. “Truly, this is a crisis within a crisis within a crisis. The community suffers from insecurity, and suffered under Ebola, and now may have to face COVID-19.” In early March, an Ebola patient whom many hoped would be the last was discharged, and the outbreak was supposed to be officially declared over Sunday. But the World Health Organization on Friday announced a new case in Beni. The outbreak has claimed more than 2,260 lives since August 2018 — the second largest the world has ever seen, after the 2014-2016 outbreak in West Africa. Still, there is some hope: Many of the tools used to fight Ebola — hand-washing and social distancing chief among them — are also key to combating the coronavirus. In Beni, which has reported two cases of the new coronavirus, “the communities here hold onto some hope that they are going to overcome this pandemic the way they had been working to overcome Ebola,” said Milonde. “They are counting on the caution, vigilance and hygiene practices that they have been performing to save their families.”  Community advocates in Beni — who walk around with megaphones to talk about Ebola — have started to include warnings about the coronavirus. Messages explaining COVID-19, the disease caused by the virus, and where to go if sick are being spread on radio stations, through text message blasts and by religious leaders. Schools, churches and mosques are already armed with hand-washing kits. Beni’s mayor, Nyonyi Bwanakawa, says many of the measures will be familiar — but the recommendations to stay home are more stringent than what is required for Ebola, and officials are prepared to take “dramatic measures” if people resist. Unlike Ebola, which kills about half of the people it infects, the new coronavirus causes mostly mild or moderate symptoms in about 80% of people. Spreading Ebola typically requires an exchange of bodily fluids, and people have often been infected when caring for loved ones or mourning in traditional funerals that involve close contact with the body. In contrast, the new coronavirus is far more contagious and mostly spread by people coughing or sneezing, including those with only mild flu-like symptoms. That means the task of controlling the virus’ spread in Congo will be massive: The government has only limited control in parts of the vast country, there are also some dense population centers with poor sanitation and infrastructure, and the country’s mineral-rich east is beset by violence from various armed groups. Dr. Michel Yao, program manager for emergency response at the WHO’s Africa office, said implementing robust testing and contact tracing will be key. But getting the community fully involved in fighting the disease might be even more important. That means not just speaking at communities, “but giving them responsibility and roles to play.” Initially, efforts to control Ebola were met with resistance, one of the major contributors to its spread. Amid the insecurity in the country’s east, superstitions arose, and some clinics to treat Ebola patients were attacked and health workers killed. The capital, Kinshasa, a tightly packed city of 14 million located on the country’s western border, remains another major worry, said Yao, who is based at WHO’s African headquarters in the neighboring Republic of Congo. “If it reaches this place, it would be a big disaster,” he said. “Africa is only partly ready,” said Yao. “If we stick to sporadic cases, this can be managed.” But many more developed countries have seen cases surge, and a sizable outbreak in Congo could easily overwhelm its hospital system. Advanced equipment to deal with severe respiratory illness, which the coronavirus can cause, is lacking: The Health Ministry says there are about 65 ventilators — all in Kinshasa — and 20 more on order for a country of more than 80 million people. There have been 215 confirmed cases of the new coronavirus in Congo, with 20 deaths, the ministry said Friday. And health workers will also need to find a way to continue to treat people infected with the many other diseases that regularly torment the population. Over the past year, for instance, a measles outbreak killed more than 6,000 people in Congo. In addition, because donor countries are themselves dealing with outbreaks, help from abroad could be less forthcoming. The key, Yao said, is training more people locally to care for the ill. The challenge will be rallying again after many months of trying to contain Ebola. “The job wasn’t yet finished, and we have to deal with another emergency,” Yao said. Katungo Methya, 53, who volunteers for the Red Cross in Beni, expressed a weariness many feel. “It’s so upsetting to have this second disease. We lost so many people through Ebola, a lot of deaths, now corona,” she said. “Everyone is really afraid.” ___ Petesch reported from Dakar, Senegal. AP medical writer Maria Cheng in London contributed from London.
[A]: Congo, weary from Ebola, must also battle the coronavirus.


[Q]: A nun attends a mass led by Pope Benedict XVI at the Garden of Gethsemane at the foot of the Mount of Olives in Jerusalem May 12, 2009, where it is believed Jesus had his final prayer before he was betrayed and arrested. REUTERS/Baz Ratner The vow of chastity taken by the world’s 95,000 Catholic nuns carries with it an increased risk of breast, ovarian and uterine cancers — all of which are more common in women who do not have children. It is a problem that has been recognized for hundreds of years. In 1713, Italian physician Bernadino Ramazzini reported nuns had extremely high rates of the “accursed pest,” breast cancer. Kara Britt of Monash University and Roger Short of the University of Melbourne, writing in The Lancet medical journal, argued that taking modern contraceptive pills could be one answer. Lack of pregnancy and lactation means childless women have more menstrual cycles, which increases cancer risk, while those who have children further decrease their risk if they have first babies while young, have several children and breastfeed. Overall mortality in women using the contraceptive pill is around 12 percent lower than in those who have never used it and the risk of developing ovarian and endometrial cancers falls by 50 to 60 percent, the authors said. “If the Catholic Church could make the oral contraceptive pill freely available to all its nuns, it would reduce the risk of those accursed pests, cancer of the ovary and uterus, and give nuns’ plight the recognition it deserves,” the doctors said. Although the Catholic Church condemns all forms of contraception, barring abstinence, the doctors argued that using the pill might still be possible under regulations on birth control set out by Pope Paul VI in Humanae Vitae in 1968. This document stated that “the Church in no way regards as unlawful therapeutic means considered necessary to cure organic diseases, even though they also have a contraceptive effect.”   Of course, the pill can also carry its own dangers, such as the risk of blood clots with the combined oestrogen-progestogen version, so the suitability of nuns would have to be assessed according to their individual medical histories, the doctors added.
[A]: Vow of chastity and the pill may keep nuns healthy.


[Q]: The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany’s Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial. Traditionally, oncologists have made treatment decisions based on where in the body a tumor started, increasingly helped by the growing knowledge of cancer’s complex genetic drivers. Under the tumor-agnostic approach, also known as pan-tumor, drugmakers skip the organ-of-origin perspective and regroup patients based only on signature genetic mutations, but success in real life will depend on the fast spread of comprehensive gene-sequencing tools for tissue samples. Individually, the mutations are so rare that cancer units are seen as unlikely to run dedicated tests for each. Roche’s Foundation Medicine supplies the comprehensive kits, competing with Thermo Fisher Scientific and Caris Life Sciences. “It’s one of the reasons we acquired Foundation Medicine, to make this comprehensive genomic profiling routine and upfront in the course of the disease,” said Daniel O’Day, the head of Roche’s Pharmaceuticals division. Loxo’s larotrectinib pill, co-developed with Bayer, was last year shown to shrink tumors in 75 percent of patients with the NTRK fusion gene anomaly, occurring in the lung, pancreas, or more than a dozen other organs. On Sunday, the response rate to larotrectinib within an enlarged group of 122 trial participants - up from 55 initially and now spanning 24 tumor types - was shown to be 81 percent. Roche said the readings from the two NTRK fusion trials were not comparable because they are made up of different patient types. Loxo’s study, for instance, included some cancers in children, while Roche plans to investigate those separately. The Roche compound is designed to tackle several oncogenic mutations and last month, it unveiled data here on entrectinib pushing back tumors in 77 percent of lung cancer patients with a mutation called ROS1. Merck & Co’s Keytruda in May last year became the first drug to win approval for pan-tumor use, though that remains a relatively small market for the mega-selling drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195. Roche Pharmaceutical’s O’Day welcomed a wider field. “Both things have to happen: You need genomic profiling and you need enough targeted medicines to encourage physicians to make that diagnosis upfront very complete. This is the world we’re entering,” he said. Though response rates could encourage a race for more such drugs, the need for suitable gene mutations or fusions will be a tall order, said oncologist Ulrik Lassen of Copenhagen’s Rigshospitalet, who co-authored the larotrectinib study. “You need to screen a lot of patients to find the needle in the haystack and the method is complicated, costly and time-consuming. When we get better at using these technologies, we can find more oncogenic fusions and companies will be smart enough to find the agents that target them.”  Roche acquired entrectinib as part of its takeover deal with U.S. cancer drug specialist Ignyta Inc for $1.7 billion, agreed in December last year. Immuno-oncology remains another major business area for Roche, which also released positive results on using its Tecentriq drug in a group of breast cancer patients with a particularly poor prognosis.
[A]:
Roche takes on Loxo, Bayer in gene-defined cancer class.